Connecting Innovations In Drug Development To Market-Leading Targeted Therapeutics

Develop, Validate & Commercialize Clinically Effective Targeted Therapeutics

After a decade of ground-breaking discussion and networking, the industry’s leading event for the precision medicine industry returns to Boston. Bringing leading biopharma, clinical, diagnostic and lab decision makers together, the 11th Clinical Biomarkers & World CDx Summit will help you overcome translational, clinical and commercial challenges facing the development of targeted therapeutics.

With three tracks designed to help you overcome your most pressing challenges, don’t miss this year’s fresh case study content exploring bioanalytical strategies, the rise of T-cell based therapeutics in personalized medicine and preparing clinical teams for unexpected crises.

Why join the Early Biomarker Development track?

  • Support your early trials with robust biomarker strategies with insights from Sanofi, Oncorus and Duke University Medical Center
  • Develop a data-driven, analytical approach to streamline your pre- and early clinical trials as Berg Health and Regeneron share their leading expertise
  • Hear from bluebird bio to help you identify relevant and informative molecular biomarkers
  • Effectively validate and translate assays for robust clinical outcomes with insights from RAPT Therapeutics and Takeda

Early Biomarker Development Expert Speakers Include:

Ekta Patel

Head, Pre-Clinical & Translational Research

Mustang Bio

Jennifer Hamilton

Executive Director & Head, Precision Medicine

Regeneron

Paul Kassner

Senior Vice President, Quantitative & Computational Biology

RAPT Therapeutics

Robert Pomponio

Global Scientific Advisor, Biomarkers & Clinical Bioanalysis TMED

Sanofi

"The only event that comprehensively addresses discovery, development, and commercialization issues in diagnostics."
Merck & Co.

Why join the Informative Clinical Data track?

  • Draw actionable insights from clinical data with insights from Cancer Research and Biostatistics
  • Join Sanofi and Incyte as they share insights into establish an effective trial strategy
  • Explore the digital world as AstraZeneca share insights into digital pathology’s role
  • Inform treatment decisions for improved patient outcomes with insights from Merck & Co., Poseida Therapeutics and University of Iowa

Informative Clinical Data Expert Speakers Include:

Ellie Corigliano

Global Director, Medical Affairs, Biomarkers & Diagnostics, Thoracic Cancer

Merck & Co.

Jason Hipp

Senior Director, Head of Pathology Data Science & Innovation, Translational Medicine

AstraZeneca

Smitha Sivaraman

Senior Director, US Medical Affairs

Incyte

Vasiliki Pelekanou

Clinical Translational Medical Lead, Oncology

Sanofi

Why join the Drug-Dx Co-Development track?

  • Overcome challenges in drug-Dx co-development with insights from Amgen and Merck on timely and cost-effective strategies
  • Develop, identify and validate the technologies you need to obtain optimal results from your trials, with insights from Cyteir Therapeutics and Novartis
  • Hear Olaris discuss why patients should be brought into your diagnostic strategy
  • Establish effective partnerships to expedite drug-Dx commercialization, with leading insights from AstraZeneca and Eisai

Drug-Dx Co-Development Expert Speakers Include:

Elizabeth O’Day

Founder & CEO

Olaris Therapeutics

Julie Ramage

Director, Precision Medicine Quality Initiatives & Partnerships

AstraZeneca

Robert Loberg

Executive Director, Clinical Biomarkers & Diagnostics

Amgen

Sid Mathur

Regulatory Affairs Director, Companion Diagnostics

Merck & Co.